Validation Of A Liquid Biopsy To Predict Recurrence In NZ Breast Cancer Patients

FIRST NAMED INVESTIGATOR: Dr Annette Lasham
HOST INVESTIGATOR: The University of Auckland

Problem
Early detection of breast cancer recurrence is critical for saving lives.

Project
Researchers have identified two molecules in the blood of 250 breast cancer patients that can predict who might have a relapse within five years after surgery. Now, they want to test these molecules on a new group of 400 New Zealand breast cancer patients to see if they can be used as a reliable blood test.

Outcome
If successful, this blood test could be combined with current medical tests to give doctors and patients better information about the likelihood of cancer returning.

Future
Using advanced statistics, researchers aim to create the best possible test to guide treatment decisions and suggest when patients might need closer monitoring after surgery.

Final Report received in July 2022
Dr. Annette Lasham's team at the University of Auckland discovered two molecules in the blood of breast cancer patients that can predict the likelihood of a relapse after surgery. Their test was 88-98% accurate, outperforming current prediction methods. This blood test could be combined with existing tests to give doctors and patients better information about the prognosis. It may also help guide treatment decisions and suggest closer monitoring of patients after surgery.